

06<sup>th</sup> February 2026

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai- 400001 <b>Scrip Code</b> - 543308 <b>ISIN</b> : INE967H01025	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 <b>Symbol</b> - KIMS <b>ISIN</b> : INE967H01025
---	---

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on 06<sup>th</sup> February 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Further to our intimation of the Board Meeting dated 02<sup>nd</sup> February 2026, the Board of Directors, at its meeting held today, inter-alia, transacted following businesses:

- **Financial Results:** Approval of the Unaudited (Standalone and Consolidated) financial results of the Company for the 03<sup>rd</sup> quarter and nine months ended 31<sup>st</sup> December 2025 together with the un-modified Limited Review Reports issued by M/s. S.R. Batliboi & Co. LLP, Chartered Accountants, Statutory Auditors of the Company and as reviewed by the Audit Committee and enclosed as "**Annexure-1**".
- **Increase of Limits for acquisition of Shares in Sarvejana Healthcare Private Limited (Material subsidiary of the Company):** The Board has accorded its consent to increase the further limit upto the tune of Rs. 100 Crores in one or more tranches for acquisition of shares of its material subsidiary from minority shareholders, the detailed disclosure pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as "**Annexure-2**".

Further, the aforesaid disclosures are also available on the website of the Company at <https://www.kimshospitals.com/investors/>.

Further, the financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Board Meeting Commenced at	-	02:30 P.M
Board Meeting Concluded at	-	06:00 P.M

**Thanking you,**  
**For Krishna Institute of Medical Sciences Limited**

**Nagajayanthi J.R**  
**Company Secretary & Compliance Officer**  
**Encl: As above**

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended December 31, 2025 and year to date from April 01, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.No.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital Bengaluru Private Limited	Subsidiary
10	Sarvejana Healthcare Private Limited	Subsidiary
11	EPANV Modioaroh Lifoooionooo Privato Limited	Subsidiary
12	KIMS Manavata Hospitals Private Limited	Subsidiary
13	Meda Institute of Podiatry Private Limited	Subsidiary
14	Chalasani Hospitals Private Limited	Subsidiary
15	Kondapur Healthcare Limited	Associate



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
  - Three subsidiaries, whose unaudited interim financial results include total revenues of Rs. 279 million and Rs. 750 million, total net loss after tax of Rs. 49 million and Rs. 157 million, total comprehensive loss of Rs. 49 million and Rs. 158 million, for the quarter ended December 31, 2025 and the period ended on that date respectively, as considered in the Statement which have been reviewed by their respective independent auditors.
  - An associate, whose unaudited interim financial results include Group's share of net loss of Rs. Nil and Rs. Nil and Group's share of total comprehensive loss of Rs. Nil and Rs. Nil for the quarter ended December 31, 2025 and for the period from April 01, 2025 to December 31, 2025 respectively, as considered in the Statement whose interim financial results, other financial information have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 is not modified with respect to our reliance on the work done and the reports of the other auditors.

**For S.R. Batliboi & Associates LLP**  
Chartered Accountants  
ICAI Firm registration number: 101049W/E300004

  
per Navneet Rai Kabra  
Partner  
Membership No.: 102328  
UDIN: 261023288SYKOT5167  
Place: Hyderabad  
Date: February 06, 2026



Statement of Unaudited Consolidated Financial Results for the Quarter and nine months period ended 31 December 2025

		(Rupees in millions)					
		Quarter ended			Nine months period ended		Year ended
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income</b>						
	(a) Revenue from operations	9,977	9,607	7,724	28,300	22,381	30,351
	(b) Other income	52	42	178	165	274	319
	<b>Total Income</b>	<b>10,029</b>	<b>9,649</b>	<b>7,902</b>	<b>28,465</b>	<b>22,655</b>	<b>30,670</b>
<b>2</b>	<b>Expenses</b>						
	(a) Purchase of medical consumables, drugs and surgical instruments	2,112	2,035	1,698	6,064	4,712	6,404
	(b) Increase in inventories of medical consumables, drugs and surgical instruments	(143)	(83)	(80)	(303)	(113)	(135)
	(c) Employee benefits expense	1,763	1,745	1,275	5,018	3,653	4,995
	(d) Other expenses	4,256	3,870	2,959	11,566	8,282	11,258
	(e) Finance costs	568	450	257	1,344	635	903
	(f) Depreciation and amortisation expenses	787	661	447	1,982	1,246	1,772
	<b>Total Expenses</b>	<b>9,343</b>	<b>8,678</b>	<b>6,556</b>	<b>25,671</b>	<b>18,415</b>	<b>25,197</b>
<b>3</b>	<b>Profit before share of loss from associate (1-2)</b>	<b>686</b>	<b>971</b>	<b>1,346</b>	<b>2,794</b>	<b>4,240</b>	<b>5,473</b>
<b>4</b>	<b>Share of loss from associate, net of tax</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>5</b>	<b>Profit before tax and exceptional items (3+4)</b>	<b>686</b>	<b>971</b>	<b>1,346</b>	<b>2,794</b>	<b>4,240</b>	<b>5,473</b>
<b>6</b>	<b>Exceptional items</b>	<b>-</b>	<b>(3)</b>	<b>-</b>	<b>(3)</b>	<b>-</b>	<b>108</b>
<b>7</b>	<b>Profit before tax (5+6)</b>	<b>686</b>	<b>968</b>	<b>1,346</b>	<b>2,791</b>	<b>4,240</b>	<b>5,581</b>
<b>8</b>	<b>Tax expense</b>						
	(a) Current tax	331	377	353	1,032	1,138	1,495
	(b) Deferred tax (credit)/charge	(164)	(129)	68	(330)	15	(62)
	<b>Total tax expenses (8)</b>	<b>167</b>	<b>248</b>	<b>421</b>	<b>702</b>	<b>1,153</b>	<b>1,433</b>
<b>9</b>	<b>Profit for the period/year (7-8)</b>	<b>519</b>	<b>720</b>	<b>925</b>	<b>2,089</b>	<b>3,087</b>	<b>4,148</b>
	<b>Attributable to:</b>						
	Owners of the company	534	669	887	1,989	2,827	3,845
	Non controlling interests	(15)	51	38	100	260	303
<b>10</b>	<b>Other comprehensive (loss)/ income for the period/year</b>						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement (loss)/gain on defined benefit plans	-	4	(12)	(2)	(42)	(31)
	- Income tax effect	-	(1)	3	-	11	8
	<b>Other comprehensive (loss)/ income, net of tax</b>	<b>-</b>	<b>3</b>	<b>(9)</b>	<b>(2)</b>	<b>(31)</b>	<b>(23)</b>
	<b>Attributable to:</b>						
	Owners of the company	-	2	(7)	(2)	(26)	(20)
	Non controlling interests	-	1	(2)	-	(5)	(3)
<b>11</b>	<b>Total comprehensive income (9+10)</b>	<b>519</b>	<b>723</b>	<b>916</b>	<b>2,087</b>	<b>3,056</b>	<b>4,125</b>
<b>12</b>	<b>Paid up equity share capital (face value of Rs.2 each)</b>						800
<b>13</b>	<b>Other Equity</b>						20,578
<b>14</b>	<b>Earnings per share (of Rs.2 each): (not annualised for the quarter/period ended)</b>						
	(a) Basic (Rs.)	1.33	1.67	2.22	4.97	7.07	9.61
	(b) Diluted (Rs.)	1.33	1.67	2.22	4.97	7.07	9.61

**Notes:**

- The above statement of unaudited consolidated financial results of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") and its associate, have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). These results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 06 February 2026. The Statutory Auditors have expressed an unmodified opinion on the consolidated financial results.
- Exceptional items pertain to valuation of call option under the call option agreements executed by the Group to acquire a majority equity stake in entities with whom the Group has Operations and Management agreements to operate and manage their hospitals.
- The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Codes"). The Codes have been made effective from 21 November 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The incremental impact of these changes, assessed by the Group, on the basis of the information available, consistent with the guidance provided by the Institute of Chartered Accountants of India, is not material to the consolidated financial results of the Group for the quarter and nine months period ended 31 December 2025. Once Central/ State Rules are notified by the Government on all aspects of the Codes, the Group will evaluate impact, if any, on the measurement of employee benefit and would provide appropriate accounting treatment.
- The Group operates in one single reportable business segment - "Medical and Healthcare services".
- The above Unaudited Consolidated Financial Results of the Group are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

Hyderabad  
06 February 2026

For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited

  
Dr. B. Bhaskara Rao  
Managing Director  
DIN: 00008985



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended December 31, 2025 and year to date from April 01, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S.R. BATLIBOI & ASSOCIATES LLP**  
Chartered Accountants  
ICAI Firm registration number: 101049W/E300004

  
per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 26102328DGAQ1H7590

Place: Hyderabad

Date: February 06, 2026



**Krishna Institute of Medical Sciences Limited**

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: [www.kimshospitals.com](http://www.kimshospitals.com), Email: CS@kimshospitals.com, Tel: 040 7122 5000

**Statement of Unaudited Standalone Financial Results for the quarter and nine months period ended 31 December 2025**


		Quarter ended			Nine months period ended		(Rupees in millions)
		31-Dec-25 (Unaudited)	30-Sep-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Dec-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Mar-25 (Audited)
<b>1</b>	<b>Income</b>						
	(a) Revenue from operations	4,419	4,300	3,475	12,453	10,382	13,841
	(b) Other income	143	125	206	390	325	567
	<b>Total Income</b>	<b>4,562</b>	<b>4,425</b>	<b>3,681</b>	<b>12,843</b>	<b>10,707</b>	<b>14,408</b>
<b>2</b>	<b>Expenses</b>						
	(a) Purchase of medical consumables, drugs and surgical instruments	860	917	752	2,558	2,088	2,795
	(b) Increase in inventories of medical consumables, drugs and surgical instruments	(45)	(63)	(57)	(131)	(48)	(42)
	(c) Employee benefits expense	744	761	571	2,187	1,782	2,364
	(d) Other expenses	1,583	1,563	1,180	4,465	3,482	4,559
	(e) Finance costs	216	178	67	519	151	232
	(f) Depreciation and amortisation expenses	226	205	149	606	426	577
	<b>Total Expenses</b>	<b>3,584</b>	<b>3,561</b>	<b>2,662</b>	<b>10,204</b>	<b>7,881</b>	<b>10,485</b>
<b>3</b>	<b>Profit before tax and exceptional items (1-2)</b>	<b>978</b>	<b>864</b>	<b>1,019</b>	<b>2,639</b>	<b>2,826</b>	<b>3,923</b>
<b>4</b>	<b>Exceptional items</b>	-	(3)	-	(3)	-	108
<b>5</b>	<b>Profit before tax (3+4)</b>	<b>978</b>	<b>861</b>	<b>1,019</b>	<b>2,636</b>	<b>2,826</b>	<b>4,031</b>
<b>6</b>	<b>Tax expense</b>						
	(a) Current tax	202	187	236	563	747	951
	(b) Deferred tax charge/(credit)	51	39	18	125	(14)	51
	<b>Total tax expenses</b>	<b>253</b>	<b>226</b>	<b>254</b>	<b>688</b>	<b>733</b>	<b>1,002</b>
<b>7</b>	<b>Profit for the period/year (5-6)</b>	<b>725</b>	<b>635</b>	<b>765</b>	<b>1,948</b>	<b>2,093</b>	<b>3,029</b>
<b>8</b>	<b>Other comprehensive (loss)/income for the period/year</b>						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement (loss)/gain on defined benefit plans	-	2	(9)	(2)	(28)	(18)
	- Income tax effect	-	-	2	1	7	5
	<b>Other comprehensive (loss)/income, net of tax</b>	<b>-</b>	<b>2</b>	<b>(7)</b>	<b>(1)</b>	<b>(21)</b>	<b>(13)</b>
<b>9</b>	<b>Total comprehensive income for the period/year (7+8)</b>	<b>725</b>	<b>637</b>	<b>758</b>	<b>1,947</b>	<b>2,072</b>	<b>3,016</b>
<b>10</b>	<b>Paid up equity share capital (face value of Rs.2 each)</b>						800
<b>11</b>	<b>Other Equity</b>						20,880
<b>12</b>	<b>Earnings per share (of Rs.2 each) : (not annualised for the quarter /period ended)</b>						
	(a) Basic (Rs.)	1.81	1.59	1.91	4.87	5.23	7.57
	(b) Diluted (Rs.)	1.81	1.59	1.91	4.87	5.23	7.57

**Notes:**

- The above statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company"), have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). These results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 06 February 2026. The Statutory Auditors have expressed an unmodified opinion on the standalone financial results.
- Exceptional items pertains to valuation of call option under the call option agreements executed by the Company to acquire a majority equity stake in entities with whom the Company has Operations and Management agreements to operate and manage their hospitals.
- The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Codes"). The Codes have been made effective from 21 November 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The incremental impact of these changes, assessed by the Company, on the basis of the information available, consistent with the guidance provided by the Institute of Chartered Accountants of India, is not material to the standalone financial results of the Company for the quarter and nine months period ended 31 December 2025. Once Central/ State Rules are notified by the Government on all aspects of the Codes, the Company will evaluate impact, if any, on the measurement of employee benefits and would provide appropriate accounting treatment.
- The Company operates in one single reportable business segment - "Medical and Healthcare services".
- The above Unaudited Standalone Financial Results of the Company are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.

Hyderabad  
06 February 2026

For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited

  
Dr. B. Bhaskara Rao  
Managing Director  
DIN: 00008985

## ANNEXURE - 2

**Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.**

a	<p><b>Name of the target entity, details in brief such as size, turnover, etc.,</b></p>	<p><b>Name of the target entity:</b> Sarvejana Healthcare Private Limited.</p> <p><b>Details in brief:</b></p> <p>Sarvejana Healthcare Private Limited ("<i>Sunshine Hospital</i>") is a material subsidiary of the Krishna Institute of Medical Sciences Limited ("the Company/ KIMS"). The Present stake of KIMS is 75.53% in Sunshine Hospital.</p> <p>The total paid up equity share capital of Sunshine Hospital as of date is ₹36,51,60,900/- (<i>Rupees Thirty-Six Crore Fifty-One Lakh Sixty Thousand Nine Hundred Only</i>) and the turnover of Sunshine Hospital for the financial year ended March 31, 2025, is ₹597.00 Cr.</p>
b	<p><b>Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of Interest and details thereof and whether the same is done at "Arms length":</b></p>	<p>Acquisition of equity shares does not fall within the definition of Related Party Transaction.</p>
c	<p><b>Industry to which the entity being acquired belongs:</b></p>	<p>Healthcare Industry</p>
d	<p><b>Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity</b></p>	<p>KIMS being the Holding Company of Sunshine Hospital, will make further investment upto Rs. 100 Crores in one or more tranches as a strategic investment to further enhance its shareholding.</p>
e	<p><b>Brief details of any governmental or regulatory approvals required for the acquisition:</b></p>	<p>Not Applicable.</p>
f	<p><b>Indicative time period for completion of the acquisition</b></p>	<p>In one or more tranches over a period of time from minority shareholders.</p>
g	<p><b>Consideration - whether cash consideration or share swap and details of the same:</b></p>	<p>Cash.</p>

h	Cost of acquisition or the price at which the shares are acquired;	The shares will be acquired from minority shareholders based on the value determined by the independent valuer.								
i	Percentage of shareholding/control acquired and/or number of shares acquired;	The present shareholding of KIMS is 75.53% in Sunshine Hospital.								
j	<b>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence, and any other significant information (in brief):</b>	<p><b>Brief background about the entity acquired:</b></p> <p>Sunshine Hospital was started in May 2009 predominantly an orthopedic hospital catering to the needs of the people with joint replacement as a core and supplementing with other high-end healthcare facilities such as cardiology, transplant., etc.,</p> <p><b>Date of Incorporation:</b> 03/12/2008</p> <p><b>History of last 3 years Total Turnover of the Company:</b></p> <table border="1" data-bbox="878 868 1437 1001"> <thead> <tr> <th>Particulars</th> <th>Amount in Crores</th> </tr> </thead> <tbody> <tr> <td>FY25</td> <td>₹597.00</td> </tr> <tr> <td>FY24</td> <td>₹464.20</td> </tr> <tr> <td>FY23</td> <td>₹419.44</td> </tr> </tbody> </table> <p><b>Presence:</b> Hyderabad, Telangana - India</p> <p><b>Other Significant Information:</b> please refer to the aforementioned.</p>	Particulars	Amount in Crores	FY25	₹597.00	FY24	₹464.20	FY23	₹419.44
Particulars	Amount in Crores									
FY25	₹597.00									
FY24	₹464.20									
FY23	₹419.44									